Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
- Resource Type
- Article
- Source
- In
The Breast October 2021 59:211-220 - Subject
- Language
- ISSN
- 0960-9776